ArticleAsian Pacific journal of cancer prevention : APJCP2025
Establishing a Decision-Making Threshold for PIVKA II in the Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC): A Single Centre Experience.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths worldwide. Due to the crucial importance of an earlier identification of PDAC, there is substantial ongoing effort to identify serological biomarkers that would facilitate the timely detection of this malignancy. Protein Induced by Vitamin K Absence II (PIVKA II), a modified prothrombin, has been recently suggested as promising diagnostic marker for PDAC detection: however, in literature no diagnostic cut-off have been proposed for PDAC diagnosis yet. Aim of this research was to identify PIVKA II decisional threshold in PDAC patients, comparing their serum values to those found in HCC patients since the clinical-diagnostic validity of PIVKA II in HCC has already been widely demonstrated.
methodsSerum PIVKA II levels were measured in 91 PDAC patients, 92 HCC patients, and 59 healthy donors using an automated chemiluminescent enzyme immunoassay. Statistical analysis, including Receiver Operating Characteristic (ROC) curves, was used to establish sensitivity, specificity, and the optimal diagnostic threshold.
resultsThe optimal PIVKA II cut-off for PDAC diagnosis was 69 ng/mL, yielding a sensitivity of 80% and specificity of 94%. Comparable performance was observed in HCC patients (sensitivity 87%, specificity 94%). PIVKA II levels distinguished PDAC patients from healthy controls and demonstrated diagnostic potential similar to HCC, suggesting a shared biomarker profile.
conclusionThis study establishes a novel cut-off for PIVKA II in PDAC, supporting its utility as a biomarker. Further research is needed to validate these findings across diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.